The "Myelofibrosis (MF) - Market Insight, Epidemiology, and Market Forecast - 2034" report has been added to ResearchAndMarkets.com's offering. The report delivers an in-depth understanding of the ...
BESREMi is a preferred, FDA-approved option for both symptomatic low- and high-risk polycythemia vera patients. In the polycythemia vera space, BESREMi faces competition from drugs like ruxolitinib, a ...
Zacks.com on MSN16d
Incyte Gears Up to Report Q4 Earnings: Here's What You Should KnowIncyte Corporation INCY is scheduled to report fourth-quarter and full-year 2024 results on Feb. 10, before the opening bell. The Zacks Consensus Estimate for the to-be-reported quarter’s revenues is ...
Opzelura is a treatment for nonsegmental vitiligo in patients 12 and older, making it the first and only cream in the U.S.
But Seneschal and colleagues were not discouraged overall. The trial "highlighted the efficacy of combining the JAK1/JAK2 inhibitor baricitinib with narrowband UV-B in the treatment of adults with ...
Data Generated to Date Support Potential for Aclaris’ ATI-2138 to Impact Several Human Inflammatory Diseases -WAYNE, Pa., Feb. 12, 2025 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback